GlaxoSmithKline’s Hal Barron poaches Genentech’s top cancer drug dealmaker for his new R&D team
Anyone looking for fresh hints about GSK’s upcoming move on the cancer front needs to check out the pharma giant’s latest hire.
New GSK R …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
